1Moncrieff, J. Antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants. BJPsych Bull 2018; 42(1): 42–4.
2Thase, ME, Trivedi, MH, Rush, AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12(3): 185–219.
3Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2): e45.
4Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357–66.
5Hieronymus, F, Lisinski, A, Nilsson, S, Eriksson, E. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Mol Psychiatry 2017; doi: 10.1038/mp.2017.147.
6Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69(6): 572–9.
7Elkin, I, Shea, MT, Watkins, JT, Imber, SD, Sotsky, SM, Collins, JF, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46(11): 971–82.
8Morrison, PD, Murray, RM. The antipsychotic landscape: dopamine and beyond. Ther Adv Psychopharmacol 2018; 8(4): 127–35.